January 19, 2018 HIPEC Increased Survival in Gastric Cancer with Peritoneal Metastasis

The goal of this study was to test the effect of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) on survival and postoperative outcomes after complete cytroreductive surgery compared with resection alone. At 3 years, HIPEC significantly improved overall survival with almost 26% of patients alive at 3 years compared with 13% of patients in the surgery alone group. The median overall survival was 18.8 months for patients treated with HIPEC compared to 12.1 months for surgery alone. Survival results at 5 years were consistent. About 20% of patients were still alive at 5 years, and 15% of patients were considered cured by HIPEC. In conclusion, cytoreductive surgery plus HIPEC improved overall survival compared with resection alone for patients with gastric cancer with peritoneal carcinomatosis.
Clinical Trials
View Full Article
Related Videos